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Propafenone: New Therapy for a
Tough, Old Arrhythmia*
FRANCIS E. MARCHLINSKI, MD, FACC
Philadelphia, Pennsvlrania
The type IC antiarrhythmic agent propafenone may be
ideally suited for the management of symptomatic atrial
fibrillation/flutter. It provides not only electrophysiologic
effects on atria) refractoriness and marked frequency-
dependent effects an atria) conduction and excitability, but
also a direct effect on the atrioventricular (AV) node, result-
ing in prolongation of AV node conduction time and refrac-
toriness (1-6) . Thus, even if the atrial fibrillation should
recur during therapy, the slower ventricular response may
preclude significant symptoms . Admittedly, our understand-
ing of the mechanism or mechanisms leading to the genesis
of atria[ fibrillation/flutter remains primitive (7) . Further-
more, although we can demonstrate pronounced electrophys-
ic ogic effects on atria[ muscle with an antiarrhythmic drug,
the mechanisms by which a drug exerts its antiarrhythmic
effect remain highly speculative (8). Thus, assessment of a
drug's efficacy in the treatment of atrial fibrillation is depen-
dent on a rigorously designed and carefully executed clinical
trial with well defined end points for defining therapeutic
success or failure.
Therapeutic efficacy of propafenone . In this issue of the
Journal, Antman and colleagues (9) present the results of
their experience using propafenone in a large group of
patients with atrial fibrillationiflutter that proved refractory
to type IA aniarrhythmic drug therapy (quinidine, procai-
namide, disopyramide)
. At 6 months, 40% of their patients
remained free from symptomatic arrhythmia recurrence .
These results, at least with respect to symptomatic arrhyth-
mia-free efficacy, are comparable with other recent reports
(10-12) in which either propafenone or amiodarone was used
to treat atria) fibrillation that proved refractory to type IA
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agents
. Prpafenone may prove more advantageous than
amiodarone because of a decreased risk of serious noncar-
diac toxicity that is commonly observed during long-term
amiodarone therapy (13,14) . Of note, exacerbation of myo-
cardial dysfunction with propafenone was not observed by
Amman and coworkers (9) . This result may have been
related to the well preserved left ventricular function (mean
ejection fraction 55%) in their study patients . Further de-
pression of systolic function has been reported after propa-
fenone therapy in patients who start with significant left
ventricular dysfunction (15) . Caution should be used when
administering propafenone for any supraventricular arrhyth-
mia in the setting of depressed ventricular function
.
The work by Amman and colleagues (9) raises three
important questions related to the assessment of the them-
peutic efficacy of an antiarrhythmic drug used in the treat-
ment of atria) fibrillation. First, how does one judge efficacy
after cardioversion of persistent atrial fibrillation? Second,
how does one judge control of paroxysmal atria[ fibrillation?
Finally, how does one assess arrhythmia control when
slowing of the ventricular response precludes the develop-
ment of symptoms during atrial fibrillation and thus the
recognition of the arrhythmia?
Assessing control after cardiovenion of atrial fibrillation.
As emphasized by Antman et al . (9), up to 50% of untreated
individuals remain in sinus rhythm for 3 to 6 months after
cardioversion of atria] fibrillation (16-19) . Does this arrhyth-
mia-free incidence differ significantly from that reported with
propafenone? One might anticipate that a study group that
includes only those patients who have been unsuccessfully
treated with type IA antiarrhythmic agents may have a
higher early recurrence rate, suggesting better control with
propafenone than would be anticipated. Unfortunately, in
the absence of a control (untreated) group, or at least the
knowledge of the outcome of a previously reported un-
treated reference group that matches the clinical character-
istics and the drug-responsiveness or unresponsiveness of
the study group, success rates <50% at 6 months of drug
therapy must he viewed with cautious optimism
.
Assessing control or paroxysmal atria) fibrillation.
The frequency with which a paroxysmal arrhythmia occurs
before evaluation is commonly ignored when judging the
efficacy of antiarrhythmic therapy . Can an arrhythmia that
occurs twice in I year be considered effectively prevented by
an antiarrhythmic drug after a 6 month arrhythmia-free
interval? Antman et al. (9) present information that strongly
suggests that most of their patients with paroxysmal atria]
fibrillation had very frequent recurrences (15 .3 arrhythmia
episodes documented during the month before initiating
treatment). They also demonstrated that the arrhythmia
incidence at 1, 6 and 12 months before treatment did not
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predict control. This finding suggests that their results were
not biased by the demonstration of success only in those
patients with infrequent arrhythmias . Thus, their findings
more likely represent a true positive beneficial effect from
propafenone therapy.
Asymptomatic recurrence of atria] fibrillation . The major
goal of antiarrhythmic therapy is the prevention of symp-
toms . Nevertheless, asymptomatic paroxysmal or persistent
atrial fibrillation may be associated with an increased risk of
embolic phenomena or may result in more insidious symp-
toms related to the loss of the contribution of atrial systole to
ventricular filling and subsequent cardiac output (2021) .
Thus, although success defined by slowing of the ventricular
response and elimination ofsymptoms is achieved, complete
arrhythmia control may not be achieved or easily rccog-
nized . To document the cardiac rhythm at the time of
symptoms, Antman et al. (9) provided patients with a
telephone electrocardiogram (ECG) transmitter for at least
the first 3 months of therapy. These efforts permitted much
more reliable symptomatic arrhythmia detection than did
previous studies that did not employ long-term
ECG surveil-
lance . Of note, asymptomatic recurrence of atria) fibrillation
was recognized in three (8%p) of their patients at the time of
routine telephonic ECG transmissions. Obviously, docu-
mentation
of all asymptomatic arrhythmia recurrences
would require continuous ECG monitoring and analysis
; a
costly, inconvenient and therefore impractical endeavor.
Nevertheless, one must recognize this limitation, particu-
larly when addressing the efficacy of the type IC antiarrhyth-
mic drugs or atniodarone in the treatment of atria) fibrilla-
tion.
Coachsionw
Most cardiologists and arrhythmologists
would agree that atrial Ph'illation tends to be a very drug-
resistant arrhythmia
. Although catheter or surgical ablative
therapy or both, has been developed for the treatment
of
drug-resistant ventricular arrhythmias, ablative therapy for
the treatment of atrial fibrillation/flutter has been almost
entirely confined to the interruption of AV conduction (22-
24) . The elimination of symptoms associated with a rapid
ventricular response is achieved; however, the arrhythmia
persists and the patient loses the contribution of atrial
systole to cardiac output and usually becomes pacemaker
dependent . We therefore greet reports
of propafenone's
effectiveness in treating atrial fibrillation with a great deal
of
enthusiasm . However, our enthusiasm should remain cau-
tious. On the basis
of
published reports
(9,10), propafenone
will probably be effective in only a minority of the patients
whose arrhythmias have proved refractory to more conven-
tional therapy. Furthermore, a longer duration of follow-up
involving a larger number of patients is required before a
significant beneficial effect can be convincingly demon-
strated in patients in whom chronic atrial fibrillation was
terminated by cardioversion after the initiation of propafe-
none therapy. Finally, the clinician must become vigilant for
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recurrences of atrial fibrillation associated with a controlled
ventricular response
. Symptoms due to decreased cardiac
output may become evident and the risk of embolic phenom-
ena may persist . Nevertheless, because of
the refractory
nature of atrial fibrillation . the addition of a new antiarrhyth-
mic agent that appears to benefit a significant
. albeit small
number of patients is welcomed.
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